Pourazizi, M., Kabiri, S. & Abtahi-Naeini, B. (2017). Intralesional bevacizumab (Avastin®) as a novel addition to infantile hemangioma management: A medical hypothesis. Journal of Research in Pharmacy Practice, 6(3), 190–191.
MLA
Pourazizi, M., Kabiri, S., & Abtahi-Naeini, B. "Intralesional bevacizumab (Avastin®) as a novel addition to infantile hemangioma management: A medical hypothesis", Journal of Research in Pharmacy Practice, 6, 3, 2017, 190–191.
HARVARD
Pourazizi, M., Kabiri, S., & Abtahi-Naeini, B. (2017). 'Intralesional bevacizumab (Avastin®) as a novel addition to infantile hemangioma management: A medical hypothesis', Journal of Research in Pharmacy Practice, 6(3), pp. 190–191.
CHICAGO
Pourazizi, M., Kabiri, S. & Abtahi-Naeini, B., "Intralesional bevacizumab (Avastin®) as a novel addition to infantile hemangioma management: A medical hypothesis." Journal of Research in Pharmacy Practice, 6 3 (2017): 190–191,
VANCOUVER
Pourazizi M., Kabiri S., Abtahi-Naeini B. Intralesional bevacizumab (Avastin®) as a novel addition to infantile hemangioma management: A medical hypothesis. Journal of Research in Pharmacy Practice. 2017;6(3):190–191.
